Our pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism, currently preparing for Phase 3 development, and a growing obesity portfolio that includes MBX 4291 in Phase 1 development, MBX 5765, a next-generation amycretin prodrug designed for once-monthly-dosing, as well as MBX 6180, a GLP/GIP/GCGR triple agonist prodrug for once monthly dosing; all of which optimize our PEP platform. This role will provide hands-on leadership on day-to-day data management activities across MBX portfolio to ensure high quality and inspection ready clinical databases and data from all sources, while serving as a key data management partner to Clinical Operations, Clinical Development, Biostatistics, Statistical Programming, Safety, Quality, Medical Writing, and external data vendors.